Nuclear pore density controls heterochromatin reorganization during senescence.


Journal

Genes & development
ISSN: 1549-5477
Titre abrégé: Genes Dev
Pays: United States
ID NLM: 8711660

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 26 09 2018
accepted: 04 12 2018
pubmed: 30 1 2019
medline: 26 2 2019
entrez: 30 1 2019
Statut: ppublish

Résumé

During oncogene-induced senescence (OIS), heterochromatin is lost from the nuclear periphery and forms internal senescence-associated heterochromatin foci (SAHFs). We show that an increased nuclear pore density during OIS is responsible for SAHF formation. In particular, the nucleoporin TPR is necessary for both formation and maintenance of SAHFs. Loss of SAHFs does not affect cell cycle arrest but abrogates the senescence-associated secretory phenotype-a program of inflammatory cytokine gene activation. Our results uncover a previously unknown role of nuclear pores in heterochromatin reorganization in mammalian nuclei and demonstrate the importance of heterochromatin organization for a specific gene activation program.

Identifiants

pubmed: 30692205
pii: gad.321117.118
doi: 10.1101/gad.321117.118
pmc: PMC6362808
doi:

Substances chimiques

Heterochromatin 0
Nuclear Pore Complex Proteins 0
Proto-Oncogene Proteins 0
RNA, Small Interfering 0
TPR protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-149

Subventions

Organisme : Medical Research Council
ID : MC_PC_U127527202
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K01563X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00007/2
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Boumendil et al.; Published by Cold Spring Harbor Laboratory Press.

Références

J Cell Sci. 1999 Jul;112 ( Pt 13):2253-64
pubmed: 10362555
J Cell Biol. 2001 Jul 9;154(1):71-84
pubmed: 11448991
J Cell Biol. 2002 Feb 18;156(4):617-30
pubmed: 11839768
Mol Biol Cell. 2003 May;14(5):1923-40
pubmed: 12802065
Cell. 2003 Jun 13;113(6):703-16
pubmed: 12809602
Dev Cell. 2005 Jan;8(1):19-30
pubmed: 15621527
Cell. 2006 Aug 11;126(3):503-14
pubmed: 16901784
J Cell Sci. 2006 Nov 1;119(Pt 21):4442-51
pubmed: 17074834
Mol Cell Biol. 2007 Mar;27(6):2343-58
pubmed: 17242207
Nature. 2008 Jun 12;453(7197):948-51
pubmed: 18463634
Science. 2008 Jun 6;320(5881):1332-6
pubmed: 18535242
Cell. 2008 Jun 13;133(6):1006-18
pubmed: 18555777
Cell. 2009 Jan 23;136(2):284-95
pubmed: 19167330
EMBO Rep. 2009 Jul;10(7):697-705
pubmed: 19543230
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
EMBO J. 2010 May 19;29(10):1659-73
pubmed: 20407419
J Cell Biol. 2010 Oct 4;191(1):15-22
pubmed: 20876277
Cell Cycle. 2011 Feb 1;10(3):457-68
pubmed: 21248468
Mol Biol Cell. 2011 Apr;22(7):1058-69
pubmed: 21289085
Nat Cell Biol. 2011 Mar;13(3):292-302
pubmed: 21336312
Genes Dev. 2011 Oct 15;25(20):2125-36
pubmed: 21979375
Dev Cell. 2012 Feb 14;22(2):446-58
pubmed: 22264802
Mol Cell. 2012 Jul 27;47(2):203-14
pubmed: 22795131
Nat Rev Mol Cell Biol. 2012 Nov;13(11):687-99
pubmed: 23090414
Cell. 2013 Jan 31;152(3):584-98
pubmed: 23374351
Nat Cell Biol. 2013 Aug;15(8):978-90
pubmed: 23770676
Genes Dev. 2013 Aug 15;27(16):1800-8
pubmed: 23964094
Nat Commun. 2015 Mar 06;6:6483
pubmed: 25744187
J Comp Neurol. 1989 Dec 15;290(3):440-50
pubmed: 2592622
Biochem J. 2017 Jan 15;474(2):281-300
pubmed: 27760841
Methods Mol Biol. 2017;1534:99-109
pubmed: 27812871
Genome Res. 2017 Oct;27(10):1634-1644
pubmed: 28916540
Sci Rep. 2017 Nov 7;7(1):14732
pubmed: 29116248
Nature. 2018 Mar 22;555(7697):475-482
pubmed: 29539637
Cell. 2018 Aug 23;174(5):1200-1215.e20
pubmed: 30100187
Genes Dev. 2018 Oct 1;32(19-20):1321-1331
pubmed: 30228202
Exp Cell Res. 1998 Nov 25;245(1):43-56
pubmed: 9828100

Auteurs

Charlene Boumendil (C)

Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom.

Priya Hari (P)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom.

Karl C F Olsen (KCF)

Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom.

Juan Carlos Acosta (JC)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom.

Wendy A Bickmore (WA)

Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH